Advertisement

Pediatric Nephrology

, Volume 27, Issue 7, pp 1103–1109 | Cite as

Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn’s disease

  • Renate Hueppelshaeuser
  • Gerd E. von Unruh
  • Sandra Habbig
  • Bodo B. Beck
  • Stephan Buderus
  • Albrecht Hesse
  • Bernd Hoppe
Original Article

Abstract

Background

Prevalence of recurrent calcium-oxalate (CaOx) urolithiasis (UL) is up to fivefold higher in Crohn’s disease than in the general population. Treatment options are scarce and the risk of recurrent UL or progressive renal CaOx deposition, (oxalosis) based early end-stage renal failure (ESRF), subsequent systemic oxalosis, and recurrence in the kidney graft is pronounced. We aimed to find proof that secondary hyperoxaluria is the main risk factor for the devastating course and correlates with intestinal oxalate absorption.

Methods

24-h urines were collected and analyzed for urinary oxalate (Uox) in 27 pediatric (6–18 years) and 19 adult patients (20–62 years). In the 21 patients (8 adults and 13 children) with hyperoxaluria a [13C2]oxalate absorption test was performed under standardized dietary conditions.

Results

Mean Uox was significantly higher in patients with UL or oxalosis (0.92 ± 0.57) compared with those without (0.53 ± 0.13 mmol/1.73 m2/24 h, p<0.05, normal < 0.5). Hyperoxaluria then significantly correlated with intestinal oxalate absorption (p< 0.05).

Conclusion

As UL/oxalosis has major implications for the general health in patients with Crohn’s disease (ESRF and systemic oxalosis), new medication, e.g. to reduce intestinal oxalate absorption, is definitely needed.

Keywords

Crohn’s disease Urolithiasis Secondary hyperoxaluria Systemic oxalosis Renal failure 

Supplementary material

467_2012_2126_MOESM1_ESM.doc (3.9 mb)
ESM 1 (DOC 3944 kb)

References

  1. 1.
    VanDervoort K, Wiesen J, Frank R, Vento S, Crosby V, Chandra M, Trachtman H (2007) Urolithiasis in pediatric patients: a single center study of incidence, clinical presentation and outcome. J Urol 177:2300–2305PubMedCrossRefGoogle Scholar
  2. 2.
    Sas DJ, Hulsey TC, Shatat IF, Orak JK (2010) Increasing incidence of kidney stones in children evaluated in the emergency department. J Pediatr 157:132–137PubMedCrossRefGoogle Scholar
  3. 3.
    Andersson H, Bosaeus I, Fasth S, Hellberg R, Hulten L (1987) Cholelithiasis and urolithiasis in Crohn's disease. Scand J Gastroenterol 22:253–256PubMedCrossRefGoogle Scholar
  4. 4.
    Hoppe B, Leumann E, von Unruh G, Laube N, Hesse A (2003) Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria. Front Biosci 8:e437–e443PubMedCrossRefGoogle Scholar
  5. 5.
    Neuhaus TJ, Belzer T, Blau N, Hoppe B, Sidhu H, Leumann E (2000) Urinary oxalate excretion in urolithiasis and nephrocalcinosis. Arch Dis Child 82:322–326PubMedCrossRefGoogle Scholar
  6. 6.
    Holmes RP, Goodman HO, Assimos DG (2001) Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int 59:270–276PubMedCrossRefGoogle Scholar
  7. 7.
    Williams HE, Wandzilak TR (1989) Oxalate synthesis, transport and the hyperoxaluric syndromes. J Urol 141:742–749PubMedGoogle Scholar
  8. 8.
    Leumann E, Hoppe B (2001) The primary hyperoxalurias. J Am Soc Nephrol 12:1986–1993PubMedGoogle Scholar
  9. 9.
    Binder HJ (1974) Intestinal oxalate absorption. Gastroenterology 67:441–446PubMedGoogle Scholar
  10. 10.
    Dobbins JW, Binder HJ (1976) Effect of bile salts and fatty acids on the colonic absorption of oxalate. Gastroenterology 70:1096–1100PubMedGoogle Scholar
  11. 11.
    Chadwick VS, Modha K, Dowling RH (1973) Mechanism for hyperoxaluria in patients with ileal dysfunction. N Engl J Med 289:172–176PubMedCrossRefGoogle Scholar
  12. 12.
    Booth CC, Babouris N, Hanna S, Macintyre I (1963) Incidence of hypomagnesaemia in intestinal malabsorption. Br Med J 2:141–144PubMedCrossRefGoogle Scholar
  13. 13.
    Trinchieri A, Lizzano R, Castelnuovo C, Zanetti G, Pisani E (2002) Urinary patterns of patients with renal stones associated with chronic inflammatory bowel disease. Arch Ital Urol Androl 74:61–64PubMedGoogle Scholar
  14. 14.
    Rudman D, Dedonis JL, Fountain MT, Chandler JB, Gerron GG, Fleming GA, Kutner MH (1980) Hypocitraturia in patients with gastrointestinal malabsorption. N Engl J Med 303:657–661PubMedCrossRefGoogle Scholar
  15. 15.
    Dobbins JW (1985) Nephrolithiasis and intestinal disease. J Clin Gastroenterol 7:21–24PubMedCrossRefGoogle Scholar
  16. 16.
    Caudarella R, Rizzoli E, Pironi L, Malavolta N, Martelli G, Poggioli G, Gozzetti G, Miglioli M (1993) Renal stone formation in patients with inflammatory bowel disease. Scanning Microsc 7:371–379, discussion 379-380PubMedGoogle Scholar
  17. 17.
    Hylander E, Jarnum S, Frandsen I (1979) Urolithiasis and hyperoxaluria in chronic inflammatory bowel disease. Scand J Gastroenterol 14:475–479PubMedGoogle Scholar
  18. 18.
    Kyle J (1980) Urinary complications of Crohn's disease. World J Surg 4:153–160PubMedCrossRefGoogle Scholar
  19. 19.
    Beck B, Habbig S, Feldkötter M, Wolf M, Bangen U, Michalk D, Stapenhorst L, Burst V, Stippel D, Fries J, Hoppe B (2008) How to handle the dilemma of ESRF and systemic oxalosis in short bowel syndrome from Crohn's disease - a potential application for Oxalobacter formigenes. Pediatr Nephrol 23:P065Google Scholar
  20. 20.
    Dick PT, Shuckett BM, Tang B, Daneman A, Kooh SW (1999) Observer reliability in grading nephrocalcinosis on ultrasound examinations in children. Pediatr Radiol 29:68–72PubMedCrossRefGoogle Scholar
  21. 21.
    Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263PubMedGoogle Scholar
  22. 22.
    Sikora P, von Unruh GE, Beck B, Feldkotter M, Zajaczkowska M, Hesse A, Hoppe B (2008) [13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria. Kidney Int 73:1181–1186PubMedCrossRefGoogle Scholar
  23. 23.
    von Unruh GE, Langer MA, Paar DW, Hesse A (1998) Mass spectrometric-selected ion monitoring assay for an oxalate absorption test applying [13C2]oxalate. J Chromatogr B: Biomed Sci Appl 716:343–349CrossRefGoogle Scholar
  24. 24.
    Hoppe B, Jahnen A, Bach D, Hesse A (1997) Urinary calcium oxalate saturation in healthy infants and children. J Urol 158:557–559PubMedCrossRefGoogle Scholar
  25. 25.
    Hylander E, Jarnum S, Jensen HJ, Thale M (1978) Enteric hyperoxaluria: dependence on small intestinal resection, colectomy, and steatorrhoea in chronic inflammatory bowel disease. Scand J Gastroenterol 13:577–588PubMedCrossRefGoogle Scholar
  26. 26.
    Hesse A, Schneeberger W, Engfeld S, Von Unruh GE, Sauerbruch T (1999) Intestinal hyperabsorption of oxalate in calcium oxalate stone formers: application of a new test with [13C2]oxalate. J Am Soc Nephrol 10 [Suppl 14]:S329–S333PubMedGoogle Scholar
  27. 27.
    Asplin JR (2002) Hyperoxaluric calcium nephrolithiasis. Endocrinol Metab Clin North Am 31:927–949PubMedCrossRefGoogle Scholar
  28. 28.
    Sikora P, Zajaczkowska M, Hoppe B (2009) Assessment of crystallization risk formulas in pediatric calcium stone-formers. Pediatr Nephrol 24:1997–2003PubMedCrossRefGoogle Scholar
  29. 29.
    Laube N, Hoppe B, Hesse A (2005) Problems in the investigation of urine from patients suffering from primary hyperoxaluria type 1. Urol Res 33:394–397PubMedCrossRefGoogle Scholar
  30. 30.
    von Unruh GE, Voss S, Sauerbruch T, Hesse A (2003) Reference range for gastrointestinal oxalate absorption measured with a standardized [13C2]oxalate absorption test. J Urol 169:687–690CrossRefGoogle Scholar
  31. 31.
    el-Habet AE, el-Sewedy SM, el-Sharaky A, Gaafar NK, Abdel-Rafee A, Hamoud F (1987) Biochemical studies on bilharzial and nonbilharzial hyperoxaluria: effect of pyridoxine and allopurinol treatment. Biochem Med Metab Biol 38:1–8PubMedCrossRefGoogle Scholar
  32. 32.
    Zimmermann DJ, Hesse A, von Unruh GE (2005) Influence of a high-oxalate diet on intestinal oxalate absorption. World J Urol 23:324–329PubMedCrossRefGoogle Scholar
  33. 33.
    Sidhu H, Schmidt ME, Cornelius JG, Thamilselvan S, Khan SR, Hesse A, Peck AB (1999) Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol 10 [Suppl 14]:S334–S340PubMedGoogle Scholar
  34. 34.
    Kumar R, Mukherjee M, Bhandari M, Kumar A, Sidhu H, Mittal RD (2002) Role of Oxalobacter formigenes in calcium oxalate stone disease: a study from North India. Eur Urol 41:318–322PubMedCrossRefGoogle Scholar
  35. 35.
    Duncan SH, Richardson AJ, Kaul P, Holmes RP, Allison MJ, Stewart CS (2002) Oxalobacter formigenes and its potential role in human health. Appl Environ Microbiol 68:3841–3847PubMedCrossRefGoogle Scholar
  36. 36.
    Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, Laube N, Kaul P, Sidhu H (2006) Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int 70:1305–1311PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2012

Authors and Affiliations

  • Renate Hueppelshaeuser
    • 1
  • Gerd E. von Unruh
    • 2
  • Sandra Habbig
    • 1
  • Bodo B. Beck
    • 3
  • Stephan Buderus
    • 5
  • Albrecht Hesse
    • 4
  • Bernd Hoppe
    • 1
  1. 1.Division of Pediatric Nephrology, Department of Pediatric and Adolescent MedicineUniversity Hospital CologneCologneGermany
  2. 2.Department of Internal Medicine IUniversity Hospital BonnBonnGermany
  3. 3.Institute of Human GeneticsUniversity Hospital CologneCologneGermany
  4. 4.Division of Experimental Urology, Department of UrologyUniversity Hospital BonnBonnGermany
  5. 5.Department of PediatricsMarien-Hospital BonnBonnGermany

Personalised recommendations